{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:39Z","timestamp":1792839699125,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Simplified approaches to hepatitis C virus (HCV) treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HCV RNA evaluations were scheduled at weeks 0, 24 (sustained viral response [SVR] visit), 48, and 72. Participants with post-entry HCV RNA \u2265 lower limit of quantification (LLoQ) had deep sequencing of NS5A and NS5B genes performed. Phylogenetic analysis distinguished between reinfection and treatment failure. Reinfection rates per 100 person-years (PYS) were calculated with 95% confidence interval (CI) constructed using Poisson distribution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 397 participants with post-entry HCV RNA, 29 had \u2265LLoQ and available sequencing data. Of those 29, 5 participants initially designated as non-SVR, and 12 participants initially attaining SVR (evaluated at week 24) were determined to have reinfections (total 17 reinfections) (reinfection rate 3.9\/100 PYS [95% CI, 2.4\u20136.2]). All 17 participants with HCV reinfection were male (13 MSM and 15 with HIV). Of 29 had \u2265LLoQ, 12 were identified as treatment failure. SVR (excluding reinfections) in presence and absence of baseline RAS was 93.5% (43\/46) and 97% (337\/346), respectively, with an overall SVR rate of 97.0% [95% CI, 94.8\u201398.3] (385\/397).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Accounting for reinfections, SVR in MINMON was 97.0% further supporting simplified HCV treatment. No significant difference in SVR was found by baseline velpatasvir RAS. The high reinfection rate, especially among men who have sex with men (MSM) with human immunodeficiency virus (HIV), underscores the need to scale-up evidence-based interventions to reduce reinfection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03512210<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae627","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T23:30:11Z","timestamp":1734391811000},"page":"1293-1301","source":"Crossref","is-referenced-by-count":3,"title":["Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3731-7960","authenticated-orcid":false,"given":"Win Min","family":"Han","sequence":"first","affiliation":[{"name":"The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre , Pathum Wan, Bangkok ,","place":["Thailand"]},{"name":"Kirby Institute, UNSW Sydney , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Suhas","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7243-4703","authenticated-orcid":false,"given":"Laura","family":"Smeaton","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre , Pathum Wan, Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Wagner Cardoso","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Infectologia Evandro Chagas, Funda\u00e7\u00e3o Oswaldo Cruz , Rio de Janeiro ,","place":["Brasil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Li","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiyappa","family":"Parvangada","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6352","authenticated-orcid":false,"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-6975","authenticated-orcid":false,"given":"Susanna","family":"Naggie","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University Medical Center , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2105-4748","authenticated-orcid":false,"given":"Ross","family":"Martin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Mo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evguenia","family":"Maiorova","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wyles","sequence":"additional","affiliation":[{"name":"Department of Medicine, Denver Health Medical Center , Denver, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025071809221373400_ciae627-B1","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024"},{"key":"2025071809221373400_ciae627-B2","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep4.1646","article-title":"Innovations in hepatitis C screening and treatment","volume":"5","author":"Patel","year":"2021","journal-title":"Hepatol Commun"},{"key":"2025071809221373400_ciae627-B3","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(23)01320-X","article-title":"Hepatitis C","volume":"402","author":"Martinello","year":"2023","journal-title":"Lancet"},{"key":"2025071809221373400_ciae627-B4","doi-asserted-by":"publisher","first-page":"ciad319","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: a meta-analysis","volume":"72","author":"Hajarizadeh","year":"2020","journal-title":"J Hepatol"},{"key":"2025071809221373400_ciae627-B6","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1016\/S2352-3018(22)00077-7","article-title":"Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression","volume":"9","author":"Hosseini-Hooshyar","year":"2022","journal-title":"Lancet HIV"},{"key":"2025071809221373400_ciae627-B7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/cid\/civ948","article-title":"Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis","volume":"62","author":"Simmons","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(21)00397-6","article-title":"A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial","volume":"7","author":"Solomon","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025071809221373400_ciae627-B9","doi-asserted-by":"crossref","first-page":"ofz076","DOI":"10.1093\/ofid\/ofz076","article-title":"Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification","volume":"6","author":"Hedskog","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025071809221373400_ciae627-B10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/1471-2164-13-475","article-title":"De novo assembly of highly diverse viral populations","volume":"13","author":"Yang","year":"2012","journal-title":"BMC Genomics"},{"key":"2025071809221373400_ciae627-B11","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"2025071809221373400_ciae627-B12","author":"SMALT"},{"key":"2025071809221373400_ciae627-B13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/10665270050081478","article-title":"A greedy algorithm for aligning DNA sequences","volume":"7","author":"Zhang","year":"2000","journal-title":"J Comput Biol"},{"key":"2025071809221373400_ciae627-B14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"2025071809221373400_ciae627-B15","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J Infect Dis"},{"key":"2025071809221373400_ciae627-B16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1128\/JCM.02624-14","article-title":"Genotype- and subtype-independent full-genome sequencing assay for hepatitis C virus","volume":"53","author":"Hedskog","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2025071809221373400_ciae627-B17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-59745-251-9_3","article-title":"Multiple alignment of DNA sequences with MAFFT","volume":"537","author":"Katoh","year":"2009","journal-title":"Methods Mol Biol"},{"key":"2025071809221373400_ciae627-B18","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/molbev\/msp077","article-title":"FastTree: computing large minimum evolution trees with profiles instead of a distance matrix","volume":"26","author":"Price","year":"2009","journal-title":"Mol Biol Evol"},{"key":"2025071809221373400_ciae627-B19","author":"FigTree"},{"key":"2025071809221373400_ciae627-B20","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1111\/liv.15705","article-title":"Determining reinfection rates by hepatitis C testing interval among key populations: a systematic review and meta-analysis","volume":"43","author":"Munari","year":"2023","journal-title":"Liver Int"},{"key":"2025071809221373400_ciae627-B21","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1\u20136 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1000","article-title":"Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial","volume":"163","author":"Everson","year":"2015","journal-title":"Ann Intern Med"},{"key":"2025071809221373400_ciae627-B23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study","volume":"65","author":"Wyles","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2021.09.038","article-title":"Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs","volume":"76","author":"Yeung","year":"2022","journal-title":"J Hepatol"},{"key":"2025071809221373400_ciae627-B25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12954-023-00801-1","article-title":"Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden","volume":"20","author":"Lindqvist","year":"2023","journal-title":"Harm Reduct J"},{"key":"2025071809221373400_ciae627-B26","volume-title":"High HCV reinfection rate in a community-based cohort of People Who Inject Drugs (PWID) in Imphal, India","author":"Kedar","year":"2023"},{"key":"2025071809221373400_ciae627-B27","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1111\/liv.14578","article-title":"Large transmission cluster of acute hepatitis C identified among HIV-positive men who have sex with men in Bangkok, Thailand","volume":"40","author":"Han","year":"2020","journal-title":"Liver Int"},{"key":"2025071809221373400_ciae627-B28","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"J Hepatol"},{"key":"2025071809221373400_ciae627-B29","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/liv.14762","article-title":"HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men","volume":"41","author":"Adu","year":"2021","journal-title":"Liver Int"},{"key":"2025071809221373400_ciae627-B30","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciac272","article-title":"High rate of hepatitis C virus reinfection among recently injecting drug users: results from the TraP Hep C program-A prospective nationwide, population-based study","volume":"75","author":"Johannesson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B31","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciae297","article-title":"Hepatitis C virus reinfection among men who have sex with men with HIV in New York City","volume":"79","author":"Fierer","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1080\/14737159.2017.1400385","article-title":"Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis","volume":"17","author":"Grebely","year":"2017","journal-title":"Expert Rev Mol Diagn"},{"key":"2025071809221373400_ciae627-B33","doi-asserted-by":"crossref","first-page":"103982","DOI":"10.1016\/j.drugpo.2023.103982","article-title":"Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: the TEMPO Pilot Study","volume":"114","author":"Grebely","year":"2023","journal-title":"Int J Drug Policy"},{"key":"2025071809221373400_ciae627-B34","doi-asserted-by":"crossref","first-page":"e26251","DOI":"10.1002\/jia2.26251","article-title":"Impact of simplified HCV diagnostic strategies on the HCV epidemic among men who have sex with men in the era of HIV oral pre-exposure prophylaxis in Taiwan: a modelling study","volume":"27","author":"Wu","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2025071809221373400_ciae627-B35","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob Health"},{"key":"2025071809221373400_ciae627-B36","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/cid\/ciad034","article-title":"Perspectives on adherence from the ACTG 5360 MINMON trial: a minimum monitoring approach with 12 weeks of sofosbuvir\/velpatasvir in chronic hepatitis C treatment","volume":"76","author":"Sowah","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025071809221373400_ciae627-B37","article-title":"SVR12 Outcomes for novel HCV genotype\/subtypes with SOF\/VEL in minmon study","author":"Han"},{"key":"2025071809221373400_ciae627-B38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2019.10.010","article-title":"Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial","volume":"72","author":"Dore","year":"2020","journal-title":"J Hepatol"},{"key":"2025071809221373400_ciae627-B39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S2468-1253(21)00012-1","article-title":"Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system","volume":"6","author":"Zhang","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025071809221373400_ciae627-B40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12072-019-09927-6","article-title":"Sofosbuvir-velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India","volume":"13","author":"Sood","year":"2019","journal-title":"Hepatol Int"},{"key":"2025071809221373400_ciae627-B41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1473-3099(14)71045-X","article-title":"Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study","volume":"15","author":"Solomon","year":"2015","journal-title":"Lancet Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae627\/61242161\/ciae627.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/6\/1293\/61242161\/ciae627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/6\/1293\/61242161\/ciae627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:22:24Z","timestamp":1752844944000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/6\/1293\/7929227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,20]]},"published-print":{"date-parts":[[2025,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae627","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,15]]},"published":{"date-parts":[[2024,12,20]]}}}